Woman with hands above head


SPRAVATO® is the first prescription nasal spray, used along with an oral antidepressant to treat:

  • Adults with treatment-resistant depression (TRD)
  • Depressive symptoms in adults with major depressive disorder (MDD) with suicidal thoughts or actions

We all know how hard it is to treat depression, but a new therapy may be helping patients stay in remission. After 16 weeks of SPRAVATO®, those who continued treatment were less likely than others stop receiving their medication and therefore had better outcomes on this regimen for longer periods!

Things to keep in mind about Spravato

  • SPRAVATO® nasal spray was evaluated for safety in both short- and long-term clinical trials of adults diagnosed with treatment-resistant depression
  • Do not take SPRAVATO® if you have a blood vessel disease (aneurysm), an abnormal connection between your blood vessels (arteriovenous malformation), a history of bleeding in the brain or if you are allergic to esketamine, ketamine or any of the ingredients in SPRAVATO®. Talk to your healthcare provider to learn more